Short-Term Outcome of Intravitreal Dexamethasone Implant for Macular Edema Secondary to Branch Retinal Vein Occlusion.

Kang, Sun Ah; Kim, Jong Woo; Kim, Chul Gu; Lee, Tae Gon; Lew, Young Ju; Kim, Jae Hui

doi:2015.56.1.39

J Korean Ophthalmol Soc > Volume 56(1); 2015 > Article

Original Article

Journal of the Korean Ophthalmological Society 2015;56(1):39-46.
DOI: https://doi.org/10.3341/jkos.2015.56.1.39 Published online January 15, 2015.

Short-Term Outcome of Intravitreal Dexamethasone Implant for Macular Edema Secondary to Branch Retinal Vein Occlusion.

Sun Ah Kang, Jong Woo Kim, Chul Gu Kim, Tae Gon Lee, Young Ju Lew, Jae Hui Kim

Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. kjh7997@daum.net

분지망막정맥폐쇄에 동반된 황반부종 환자에서 덱사메타손 유리체강내 삽입물의 단기임상결과

강선아⋅김종우⋅김철구⋅이태곤⋅유영주⋅김재휘

Department of Ophthalmology, Kim’s Eye Hospital, Konyang University College of Medicine, Seoul, Korea

Abstract

PURPOSE
To evaluate short-term outcomes of intavitreal dexamethasone implant in macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: A retrospective review of medical records was performed for 24 patients (24 eyes) who were diagnosed with macular edema secondary to BRVO. The best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were measured before the injection and at 1 and 3 months after the injection. The values measured before and after the treatment were compared. In addition, the association between duration of symptoms and 3-month changes in BCVA was evaluated. RESULTS: In 24 eyes, the logarithm of minimal angle of resolution BCVA before the injection and 1 and 3 months after the injection was 0.56 +/- 0.25, 0.42 +/- 0.26 and 0.45 +/- 0.27, respectively. The CFT was 550.2 +/- 116.5 microm, 270.3 +/- 101.5 microm, and 356.6 +/- 173.7 microm, respectively. When compared with the baseline values, the BCVA at 3 months was significantly improved (p = 0.018) and the CFT was significantly decreased (p < 0.001). There was a significant negative association between the duration of symptoms and 3-month changes in BCVA (p = 0.032, r = -0.375). Elevated intraocular pressure was observed in 3 eyes (12.5%). CONCLUSIONS: Intravitreal dexamethasone implant was found effective in treating macular edema secondary to BRVO. However, rebound macular edema and deterioration in visual acuity after 1 month suggest further studies with longer follow-ups are necessary.

Key Words: Clinical outcome;Dexamethasone;Ozurdex;Retinal vein occlusion